Despite significant scientific efforts, the standard of care treatment for GBM is still surgery, followed by radiotherapy and TMZ, with only evaluation of IDH mutations and methylation of MGMT as molecular markers of routine to classify and treat the disease. The gene discussed is IDH2; the disease is glioblastoma.